RLAY vs WRBY: Which Stock Is the Better Buy?
Relay Therapeutics, Inc. and Warby Parker Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RLAY vs WRBY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Relay Therapeutics, Inc. (RLAY) | Warby Parker Inc. (WRBY) | |
|---|---|---|
| Market cap | $3.1B | $3.2B |
| Revenue (latest FY) | $15.36M | $871.90M |
| Net income (latest FY) | $-276.48M | $1.64M |
| Revenue growth (5y CAGR) | -28.6% | 17.2% |
| Net margin | -1800.6% | 0.2% |
| Return on equity | -48.8% | 0.4% |
| P/E ratio | — | 2581.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RLAY vs WRBY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RLAY's full financials → Open WRBY's full financials →More comparisons
Frequently asked questions
Which is bigger, RLAY or WRBY?
Warby Parker Inc. is larger by market capitalization — $3.2B versus $3.1B.
Which grows faster, RLAY or WRBY?
Over the last five fiscal years, Warby Parker Inc. grew revenue faster — 17.2%/yr versus -28.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
RLAY fundamentals → · WRBY fundamentals → · All 1,500+ companies → · Free screener →